Reaction: Escitalopram to 1 product
- Reaction
- Reaction type
- deamination
- Direction
- Major circulating metabolite?
- No
- Spontaneous?
- No
- Activity
- unknown
- References
- Rudberg I, Reubsaet JL, Hermann M, Refsum H, Molden E: Identification of a novel CYP2C19-mediated metabolic pathway of S-citalopram in vitro. Drug Metab Dispos. 2009 Dec;37(12):2340-8. doi: 10.1124/dmd.109.029355. Epub 2009 Sep 22. [Article]
- Rao N: The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002. [Article]
- Baumann P, Zullino DF, Eap CB: Enantiomers' potential in psychopharmacology--a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol. 2002 Oct;12(5):433-44. doi: 10.1016/s0924-977x(02)00051-2. [Article]
- von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI: Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001 Aug;29(8):1102-9. [Article]
- Comments
- Not Available
- Enzymes
Enzyme Km Vmax Role Amine oxidase [flavin-containing] A Not Available Not Available implied Amine oxidase [flavin-containing] B Not Available Not Available implied
